Literature DB >> 28755839

Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: 2. Relationship to amyloid β immunotherapy.

Andrés Crane1, William D Brubaker1, Jenny U Johansson1, Abhishek Trigunaite1, Justine Ceballos1, Bonnie Bradt1, Courtney Glavis-Bloom1, Tanya L Wallace1, Andrea J Tenner2, Joseph Rogers3.   

Abstract

INTRODUCTION: Our previous studies have shown that amyloid β peptide (Aβ) is subject to complement-mediated clearance from the peripheral circulation, and that this mechanism is deficient in Alzheimer's disease. The mechanism should be enhanced by Aβ antibodies that form immune complexes (ICs) with Aβ, and therefore may be relevant to current Aβ immunotherapy approaches.
METHODS: Multidisciplinary methods were employed to demonstrate enhanced complement-mediated capture of Aβ antibody immune complexes compared with Aβ alone in both erythrocytes and THP1-derived macrophages.
RESULTS: Aβ antibodies dramatically increased complement activation and opsonization of Aβ, followed by commensurately enhanced Aβ capture by human erythrocytes and macrophages. These in vitro findings were consistent with enhanced peripheral clearance of intravenously administered Aβ antibody immune complexes in nonhuman primates. DISCUSSION: Together with our previous results, showing significant Alzheimer's disease deficits in peripheral Aβ clearance, the present findings strongly suggest that peripheral mechanisms should not be ignored as contributors to the effects of Aβ immunotherapy.
Copyright © 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid β peptide; Aβ immunotherapy; Blood; Complement; Complement receptor 1; Erythrocyte; Human; Macrophage

Mesh:

Substances:

Year:  2017        PMID: 28755839      PMCID: PMC5881571          DOI: 10.1016/j.jalz.2017.04.015

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  40 in total

Review 1.  Immune adherence revisited: novel players in an old game.

Authors:  Christoph Hess; Jürg A Schifferli
Journal:  News Physiol Sci       Date:  2003-06

2.  Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

Authors:  P D Mehta; T Pirttilä; S P Mehta; E A Sersen; P S Aisen; H M Wisniewski
Journal:  Arch Neurol       Date:  2000-01

3.  Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide.

Authors:  S Webster; B Bradt; J Rogers; N Cooper
Journal:  J Neurochem       Date:  1997-07       Impact factor: 5.372

4.  Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.

Authors:  Ronald B DeMattos; Kelly R Bales; David J Cummins; Steven M Paul; David M Holtzman
Journal:  Science       Date:  2002-03-22       Impact factor: 47.728

5.  C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion.

Authors:  S W Tas; L B Klickstein; S F Barbashov; A Nicholson-Weller
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

Review 6.  NMDA receptor antibody encephalitis.

Authors:  Sarosh R Irani; Angela Vincent
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

7.  Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy.

Authors:  J B Mackic; M H Weiss; W Miao; E Kirkman; J Ghiso; M Calero; J Bading; B Frangione; B V Zlokovic
Journal:  J Neurochem       Date:  1998-01       Impact factor: 5.372

Review 8.  Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.

Authors:  Delphine Boche; Nathan Denham; Clive Holmes; James A R Nicoll
Journal:  Acta Neuropathol       Date:  2010-07-15       Impact factor: 17.088

9.  beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain.

Authors:  H Jiang; D Burdick; C G Glabe; C W Cotman; A J Tenner
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

10.  A coding variant in CR1 interacts with APOE-ε4 to influence cognitive decline.

Authors:  Brendan T Keenan; Joshua M Shulman; Lori B Chibnik; Towfique Raj; Dong Tran; Mert R Sabuncu; April N Allen; Jason J Corneveaux; John A Hardy; Matthew J Huentelman; Cynthia A Lemere; Amanda J Myers; Anne Nicholson-Weller; Eric M Reiman; Denis A Evans; David A Bennett; Philip L De Jager
Journal:  Hum Mol Genet       Date:  2012-02-17       Impact factor: 6.150

View more
  13 in total

1.  Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: Polymorphisms, structure, and function of complement receptor 1.

Authors:  Jenny U Johansson; William D Brubaker; Harold Javitz; Andrew W Bergen; Denise Nishita; Abhishek Trigunaite; Andrés Crane; Justine Ceballos; Diego Mastroeni; Andrea J Tenner; Marwan Sabbagh; Joseph Rogers
Journal:  Alzheimers Dement       Date:  2018-05-21       Impact factor: 21.566

Review 2.  Let's make microglia great again in neurodegenerative disorders.

Authors:  Marie-Victoire Guillot-Sestier; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2017-10-12       Impact factor: 3.575

Review 3.  Complement-Mediated Events in Alzheimer's Disease: Mechanisms and Potential Therapeutic Targets.

Authors:  Andrea J Tenner
Journal:  J Immunol       Date:  2020-01-15       Impact factor: 5.422

4.  Inflammation, negative affect, and amyloid burden in Alzheimer's disease: Insights from the kynurenine pathway.

Authors:  Auriel A Willette; Colleen Pappas; Nathan Hoth; Qian Wang; Brandon Klinedinst; Sara A Willette; Brittany Larsen; Amy Pollpeter; Tianqi Li; Scott Le; Ana D Collazo-Martinez; Jonathan P Mochel; Karin Allenspach; Robert Dantzer
Journal:  Brain Behav Immun       Date:  2021-03-26       Impact factor: 19.227

5.  Letter.

Authors:  Ara S Khachaturian
Journal:  Alzheimers Dement (Amst)       Date:  2017-11-21

6.  Clearance of amyloid-beta with bispecific antibody constructs bound to erythrocytes.

Authors:  Ronald P Taylor; Margaret A Lindorfer; John P Atkinson
Journal:  Alzheimers Dement (N Y)       Date:  2020-08-27

7.  Systematic analysis of dark and camouflaged genes reveals disease-relevant genes hiding in plain sight.

Authors:  Mark T W Ebbert; Tanner D Jensen; Karen Jansen-West; Jonathon P Sens; Joseph S Reddy; Perry G Ridge; John S K Kauwe; Veronique Belzil; Luc Pregent; Minerva M Carrasquillo; Dirk Keene; Eric Larson; Paul Crane; Yan W Asmann; Nilufer Ertekin-Taner; Steven G Younkin; Owen A Ross; Rosa Rademakers; Leonard Petrucelli; John D Fryer
Journal:  Genome Biol       Date:  2019-05-20       Impact factor: 13.583

Review 8.  Peripheral clearance of brain-derived Aβ in Alzheimer's disease: pathophysiology and therapeutic perspectives.

Authors:  Yuan Cheng; Ding-Yuan Tian; Yan-Jiang Wang
Journal:  Transl Neurodegener       Date:  2020-05-07       Impact factor: 8.014

9.  Inherited and Acquired Decrease in Complement Receptor 1 (CR1) Density on Red Blood Cells Associated with High Levels of Soluble CR1 in Alzheimer's Disease.

Authors:  Rachid Mahmoudi; Sarah Feldman; Aymric Kisserli; Valérie Duret; Thierry Tabary; Laurie-Anne Bertholon; Sarah Badr; Vignon Nonnonhou; Aude Cesar; Antoine Neuraz; Jean Luc Novella; Jacques Henri Max Cohen
Journal:  Int J Mol Sci       Date:  2018-07-25       Impact factor: 5.923

10.  Elovanoids counteract oligomeric β-amyloid-induced gene expression and protect photoreceptors.

Authors:  Khanh V Do; Marie-Audrey I Kautzmann; Bokkyoo Jun; William C Gordon; Robert Nshimiyimana; Rong Yang; Nicos A Petasis; Nicolas G Bazan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.